Biopharmaceuticals Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Biopharmaceuticals Market Trends and Insights

Anti-cancer Monoclonal Antibodies are Expected to Witness Significant Growth Over the Forecast Period in the Biopharmaceutical Market

Anti-cancer Monoclonal Antibodies (also called moAbs or mAbs) are a class of Biologics made in laboratories that act like antibodies and treat cancer. They work in different ways to kill cancer cells or inhibit their growth further. The rising usage of monoclonal antibodies and antibody derivatives in therapeutics to treat cancer is a key driver for the rapid growth of the Monoclonal Antibodies Market.

Growing approvals, clinical trials, and increasing research expenditure are major factors contributing to this segment's growth. For instance, in October 2022, PT217, a bispecific anti-Delta-like ligand 3 (DLL3)/anti-Cluster of Differentiation 47 (CD47) antibody, developed by Phanes Therapeutics, Inc., received Phase 1 clearance from the United States Food and Drug Administration (FDA). Phanes Therapeutics, Inc. is a clinical-stage Biopharmaceutical Research Company focused on oncology for patients with small cell lung cancer (SCLC) and other neuroendocrine cancers.

Additionally, the growing number of FDA approvals and new product launches for various indications will drive the segment. For instance, in January 2022, the FDA approved Kimmtrak for treating HLA-A-positive adult patients with unresectable or metastatic uveal melanoma, a rare type of cancer that originates in the eye. Similarly, in May 2022, Roche Pharma launched Phesgo, a combination of Monoclonal Antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, for the treatment of patients with breast cancer.

Thus, the Monoclonal Antibodies Market segment is likely to witness significant growth over the forecast period due to the above-mentioned factors.

North America is Expected to Hold a Significant Share of the Market Over the Forecast Period

As per Biopharmaceutical Analysis, the growing burden of chronic diseases, the rising geriatric population, and increasing investments in research and development activities in the region are the major factors driving the Biopharmaceuticals Market in North America. In addition, the presence of well-established Biopharmaceutical Companies and new product launches are also expected to boost market growth in the region.

The rising prevalence of chronic diseases in the United States is likely to facilitate market growth in the region. For instance, the Centers for Disease Control and Prevention's (CDC) data updated in July 2022 briefed that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults aged 20 and older suffer from the ailment in the United States. Additionally, per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack annually. Thus, the high burden of cardiovascular diseases demands the availability of advanced drugs for treatment, which is likely to boost the Biopharma Market Growth.

Furthermore, an increase in the incidences of chronic diseases among the Canadian population, as well as the comorbidities associated with the diseases, is expected to positively impact the growth of the Biopharmaceuticals Market over the forecast period. For instance, according to Statistics Canada, as of July 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. As the geriatric population is more prone to chronic diseases, the rising elderly population is likely to raise the demand for effective drugs for their treatment hence, expected to drive the market growth over the forecast period.

Furthermore, strategic activities such as acquisitions and rising investments by key market players to expand their footprint in the Biopharmaceuticals Industry are also expected to propel market growth. For instance, in May 2022, Eli Lilly and Company announced an investment of USD 2.1 billion to expand its manufacturing footprint in Indiana, United States. Similarly, in May 2022, LOTTE acquired Bristol Myers Squibb's manufacturing facility in East Syracuse, New York. The East Syracuse site will serve as the LOTTE Center for North America Operations for LOTTE's new Biologics contract development and manufacturing organization (CDMO) business in the United States.

Thus, due to the factors mentioned above, such as rising chronic disease prevalence and the company's investment and acquisition strategy, the studied market is expected to grow significantly in North America over the forecast period.

Regulatory Landscape

The global biopharmaceuticals regulatory environment continues to tighten around evidence standards and manufacturing controls, while it clarifies pathways for complex biologics and biosimilars. In March 2026, the US FDA issued updated draft Q&As for biosimilar development under the BPCI Act section 351(k) pathway, reinforcing current expectations on demonstrating biosimilarity and the evidence package needed for abbreviated licensure. In the EU, the European Medicines Agency (EMA) adopted a March 2026 reflection paper on a tailored clinical approach for biosimilars, supporting development strategies that rely more heavily on analytical characterization and, where justified, reduced comparative clinical efficacy studies.

Manufacturing and lifecycle change control remain central compliance themes for both originator biologics and biosimilars. The EMA implemented a revised stability testing guideline for marketing authorization variations effective January 15, 2026, and its GMP/GDP Inspectors Working Group advanced a concept paper in January 2026 to revise Annex 15 (qualification and validation) aligned to ICH Q9(R1) quality risk management. In China, the State Council implemented new rules effective May 1, 2026 governing clinical research and translational application of new biomedical technologies, alongside revised Drug Administration Law implementation regulations effective May 15, 2026 that emphasize coordinated oversight of supply resilience and essential medicine management, adding another compliance layer for global companies operating across regions.

Market Opportunities and Future Outlook

Manufacturing scale-up and outsourcing capacity are expanding across drug substance and sterile fill-finish, creating room for CDMOs and suppliers that can meet biologics quality and tech-transfer demands. In June 2026, Recipharm announced a multi-million-dollar investment to expand US sterile fill-and-finish capabilities for biologics and advanced therapies, and in July 2026 Bora Biologics added a commercial manufacturing site in Rockville, Maryland, lifting installed US single-use bioreactor capacity to 20,000 liters (scalable to 30,000 liters). Lonza also announced an expansion of antibody-drug conjugate (ADC) manufacturing at its Visp, Switzerland, hub, adding payload-linker production and purification capacity, planned to become operational in 2028. The focus on higher-complexity biologics modalities is continuing to pull through in capacity and capability investments.

Process modernization and data-driven development are a near-term execution area for firms looking to standardize data, validation, and lifecycle governance in line with regulator expectations. BioPhorum published its Technology Strategy Maturity Matrix (TSMM) in April 2026 to guide large-scale biomanufacturing organizations in adopting digitally enabled manufacturing and AI- and machine-learning-augmented process design. Separately, the FDA and EMA jointly published guiding principles for Good AI Practice in Drug Development (January 2026), which clarifies how companies may frame compliance when deploying AI across the drug lifecycle, from development through manufacturing and post-approval change management.